Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.
The immunotherapy drug pembrolizumab (Keytruda) can now be used to treat some patients with Hodgkin lymphoma on the NHS in England.
Hodgkin lymphoma patients can be spared the serious side effects of chemotherapy thanks to high-tech scans that can predict the outcome of treatment.
Cancer Research UK’s Drug Development Office (DDO) has launched a vaccine trial to treat some forms of cancer caused by the Epstein Barr Virus (EBV).
A vaccine to prevent infection with a common herpes virus, the Epstein-Barr Virus (EBV), could help prevent 200,000 new cancers worldwide per year.
TWO THIRDS of Hodgkin’s lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research*, today (Tuesday).
Cases of non-Hodgkin lymphoma have more than tripled in the last thirty years according to the latest Cancer Research UK figures published today.
Children treated for Hodgkin’s disease before 1986 have an increased risk of developing another cancer later in life, according to a new study1 by an international team of researchers including scientists from Cancer Research UK.